T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC

T Cell-Activating Mesenchymal Stem Cells as a Biotherapeutic for HCC

The outcome for advanced stage hepatocellular carcinoma (HCC) remains poor, highlighting the need for novel therapies. Genetically modified mesenchymal stem cells (MSCs) are actively being explored as cancer therapeutics due to their inherent ability to migrate to tumor sites. We reasoned that MSCs...

Full description

Bibliographic Details
Main Authors: Arpad Szoor, Abishek Vaidya, Mireya Paulina Velasquez, Zhuyong Mei, Daniel L. Galvan, David Torres, Adrian Gee, Andras Heczey, Stephen Gottschalk
Format: Article
Language:English
Published: Elsevier 2017-09-01
Series:Molecular Therapy: Oncolytics
Subjects:
hepatocellular carcinoma
GPC3
bispecific antibody
immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770517300293

Internet

http://www.sciencedirect.com/science/article/pii/S2372770517300293

Similar Items